Rhythm Pharmaceuticals, Inc. - Special Call Transcript
Good morning, and welcome to the Rhythm's Pharmaceuticals' conference call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
At this time, I would like to turn the call over to Hannah Deresiewicz with Stern Investment Relations. Please proceed.
Thank you, operator. Good morning, everyone, and thank you for joining us today to review the updated clinical data for setmelanotide and MC4R Pathway Heterozygous or HET obesity that were announced earlier this morning. You can access the press release for the data as well as the slides that we'll be reviewing today by going to the Investors and Media section of the Rhythm website at www.rhythmtx.com.
With me today with prepared remarks is Dr. Keith Gottesdiener, Chief Executive Officer of Rhythm; Dr. Murray Stewart, Chief Medical Officer; Nithya Desikan, Chief Commercial Officer; and Hunter Smith, Chief Financial
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |